About the company
Algentech is a green biotech company, specialized in synthetic biology, using its proprietary plant bioproduction platform for the valorization of bio-based components for industry.
Algentech is positioned as a partner, supplier of value-added biobased ingredients for multisectorial applications, harnessing the natural power of plants to sustainably produce biobased products for pharmaceutical, cosmetic and food industries.
The company is a member of the Genopole BioCluster and performs its R&D activities at the University of Paris Saclay.
Our mission is to produce best in class bioproducts combining production efficiency with a positive environmental impact
Dr Sorokin has a PhD in plant genetics obtained from the Institute of Genetics and Cytology, Minsk. Extensive experience in plant biotechnology and business development. Held several positions as a group leader at the Sainsbury's laboratory in Norwich (UK) and as Head of Innovation at Plant Bioscience Ltd in Norwich (UK). Co-inventor of 7 patents in synthetic biology. Finalist of the 2021 EurekAwards, a competition to discover and support ambitious synthetic biology projects across Europe. Nationality: British.
Alexander Sorokin
Dr Malcuit holds a PhD in plant virology from Trinity College (Dublin, Ireland). Dr Malcuit has extensive experience in plant biotechnology and business development in the biotech sector. Prior to founding Algentech, she held the position of senior research associate at the Sainsbury Laboratory (Norwich, UK). She is co-inventor on 7 patent families owned by Algentech.
Isabelle Malcuit
Alena Sarokina
Masters in Biochemistry from Minsk University. Over 13 years experience in plant biotechnology. In charge of the plant transformation platform.
Jana Maslovaric
Masters in Systems and Synthetic Biology from Evry University. In charge of melanin production and purification
Nathalie Ricoeur Nicolai
PhD in economy; founder of Scientipole capital, former project manager at Scientipôle Initiative. Former Deputy Director of economic and financial research at CDC IXIS. AMF Certification
Laurent Bracco
Ph.D in Molecular Biology: conducted research programs in Oncology within Sanofi before co-founding ExonHit Therapeutics, a gene profiling biotech.
Michel Martin
IT specialist, graduated from ENSEM (Ecole Nationale Supérieure d’Electricité et de Mécanique) and IAE Paris business school; Secretary General at IEAM Paris
Jacques Tamisier
Polytechnique graduate, Scientific Attaché of US French Embassy in Washington DC; member of Oncodiag strategic board; vice-president of France Angels; former executive director of Orange
Henri Jannet
Polytechnique graduate, Chairman and CEO of Business Angels des Grandes Ecoles (Badge), one of the most important French networks of Business Angels. Former CEO of Sanef Group
Frédéric Zampatti
Graduated from Toulouse Business School & Master in finance from Nice University. CEO of Algenscribe. Former Director of Investment at Scientipole Capital and former Deputy CEO of Nutrivercell.
Alain Verlière
30 years in pharmaceutical industry (Roussel, HMR, Aventis, Sanofi) in France as well as foreign countries as CFO, Country head, VP Latin America Zone and Business Development positions.
Jean-Thierry Augustin
Former CEO of Eurosport. Now consultant in major sports related transactions. Investor in various ventures, predominantly e-sports, gaming related and life science
Ours partners
